Nektar Therapeutics (NKTR) announced positive results from the SUMMIT-07 Phase 3 efficacy study of its painkiller drug known as NKTR-181. The drug, which is a first-in-class opioid analgesic is a new chemical entity (NCE). It is the first full mu-opioid agonist molecule designed to provide potent pain relief without leading to abuse and addiction. The FDA has granted NKTR-181 Fast Track designation for moderate to severe chronic pain.
In a human abuse potential study, NKTR-181 has demonstrated strong analgesic effect on chronic pain while demonstrating significantly lower abuse potential . . .
This content is for paid subscribers.
Today’s Highlights March 20, 2017